A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1
Open Access
- 12 August 2010
- journal article
- Published by American Society of Hematology in Blood
- Vol. 116 (6), 893-899
- https://doi.org/10.1182/blood-2010-03-273151
Abstract
Eliglustat tartrate (Genz-112638), a specific inhibitor of glucosylceramide synthase, is under development as an oral substrate reduction therapy for Gaucher disease type 1 (GD1). A multinational, open-label, single-arm phase 2 study of 26 GD1 patients (16 female, 10 male; mean age, 34 years) evaluated the efficacy, safety, and pharmacokinetics of eliglustat tartrate administered twice daily by mouth at 50- or 100-mg doses based on plasma drug concentrations. Entry criteria required splenomegaly with thrombocytopenia and/or anemia. The composite primary efficacy end point required improvement after 52 weeks in at least 2 of these 3 disease manifestations and was met by 77% (95% confidence interval [CI] = 58%-89%) of all patients and 91% (95% CI = 72%-98%) of the 22 patients completing 52 weeks. Statistically significant improvements occurred in mean hemoglobin level (1.62 g/dL; 95% CI =1.05-2.18 g/dL), platelet count (40.3%; 95% CI = 23.7-57.0 g/dL), spleen volume (−38.5%; 95% CI = −43.5%-−33.5%), liver volume (−17.0%; 95% CI = −21.6%-12.3%), and lumbar spine bone mineral density (0.31 Z-score; 95% CI = 0.09-0.53). Elevated biomarkers (chitotriosidase; chemokine CCL18; angiotensin-converting enzyme; tartrate-resistant acid phosphatase) decreased by 35% to 50%. Plasma glucosylceramide and ganglioside GM3 normalized. Eliglustat tartrate was well tolerated: 7 mild, transient adverse events in 6 patients were considered treatment-related. Individual pharmacokinetics varied; mean time to maximal observed concentration was 2.3 hours and mean half-life was 6.8 hours. Eliglustat tartrate appears to be a promising oral treatment for GD1. This study is registered at www.clinicaltrials.gov as #NCT00358150.Keywords
This publication has 20 references indexed in Scilit:
- Safety, Tolerability, and Pharmacokinetics of Eliglustat Tartrate (Genz-112638) After Single Doses, Multiple Doses, and Food in Healthy VolunteersThe Journal of Clinical Pharmacology, 2011
- Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1Genetics in Medicine, 2009
- Official Positions of the International Society for Clinical Densitometry and Executive Summary of the 2007 ISCD Position Development ConferenceJournal of Clinical Densitometry, 2008
- Effect of Miglustat on Bone Disease in Adults with Type 1 Gaucher Disease: A Pooled Analysis of Three Multinational, Open-Label StudiesClinical Therapeutics, 2007
- A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher diseaseMolecular Genetics and Metabolism, 2007
- Effect of Enzyme Replacement Therapy With Imiglucerase on BMD in Type 1 Gaucher DiseaseJournal of Bone and Mineral Research, 2007
- Gaucher disease in Colombia: Mutation identification and comparison to other hispanic populationsMolecular Genetics and Metabolism, 2005
- Assessing Individual Outcomes during Outpatient Multidisciplinary Chronic Pain Treatment by Means of an Augmented SF-36Pain Medicine, 2000
- Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.JCI Insight, 1994
- Analogs of ceramide that inhibit glucocerebroside synthetase in mouse brainChemistry and Physics of Lipids, 1980